Development of a mimotope-based vaccine against CD20 antigen.
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Li
Meng
M
Center of Biotechnology, the Fourth Military Medical University, 17 Changle West Road, Xi'an, China.
Han
Wei
W
Zhang
Quiyang
Q
Xue
Xiaochang
X
Wang
Zenglu
Z
Zhang
Yingqi
Y
D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood / Q000276:immunology; D018951:Antigens, CD20 / Q000097:blood / Q000737:chemistry / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D000939:Epitopes; D005822:Genetic Vectors; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D010452:Peptide Biosynthesis; D010957:Plasmids; D022223:Vaccines, Subunit / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use
D000912:Antibodies, Neoplasm; D018951:Antigens, CD20; D019496:Cancer Vaccines; D000939:Epitopes; D022223:Vaccines, Subunit